Avantax Advisory Services Inc. decreased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 36.9% in the ...

In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on Idexx Laboratories (IDXX – Research Report), with a price ...

Idexx's financial health is strong. The firm had historically funded its expansions and acquisitions primarily through its own cash generation and held virtually no long-term debt until 2014. Unlike ...

Bank of America increased their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th.

IDEXX Laboratories, Inc. IDXX is well-poised ... Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished ...

Upgraded IDEXX to 'Buy' with a $450 price target due to oncology business expansion and share repurchase program. IDEXX's oncology market entry with Cancer Dx panel in March 2025 could drive ...

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...